RE:AstraZeneca's ADC disappoints - on severe adverse eventsMay 21, 2024 - Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth beyond 2030, the Company will continue investing in transformative new technologies and platforms that will shape the future of medicine.
https://www.biospace.com/article/releases/astrazeneca-sets-ambition-to-deliver-80-billion-total-revenue-by-2030-and-sustained-growth-post-2030/